Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Pseudarthrosis After Fusion or Arthrodesis
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Ovarian Carcinoma, Ovarian Germ Cell Tumor
Interventions: Laboratory Biomarker Analysis, Screening Questionnaire Administration, Ultrasound Imaging; Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 55 Years to 74 Years · Female only
Enrollment: 78,216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hearing Loss, Adult-Onset, Hearing Loss, Age-Related
Interventions: Patient Navigation Program for Hearing Health Care; Behavioral
Lead sponsor: Matthew Bush, MD; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Campbellsville, Kentucky • Campton, Kentucky • Elkton, Kentucky + 4 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 652
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more

Conditions: Neoplasms
Interventions: Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide; Drug
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 10 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 24
States / cities: Duarte, California • Stanford, California • Denver, Colorado + 19 more

Conditions: Neuroblastoma
Interventions: Dinutuximab, NK Cells, Lenalidomide; Drug · Biological
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: Up to 30 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 8 more

Conditions: Ganglioneuroblastoma, Ganglioneuroma, Neuroblastoma
Interventions: Computed Tomography, Gallium Ga 68-DOTATATE, Positron Emission Tomography; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: Up to 30 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Thymoma, Mediastinal Tumor, Gynecologic Disease, Gynecologic Cancer, Pelvic Organ Prolapse, Prostate Disease, Prostate Cancer, Inguinal Hernia, Ventral Hernia, Obesity, Morbid
Interventions: Robotic-assisted Surgery; Device
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 21 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Orlando, Florida • Lansing, Michigan • Ridgewood, New Jersey + 1 more

Conditions: Esophagectomy
Interventions: Esophagectomy, Pyloroplasty; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 85 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Covid19, Diabetes
Interventions: Not listed
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Sanfilippo Syndrome Type A
Interventions: GC1130A; Drug
Lead sponsor: GC Biopharma Corp; Industry
Eligibility: 12 Months to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Oakland, California • Minneapolis, Minnesota

Conditions: Multiple Myeloma
Interventions: Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Stichting European Myeloma Network; Network
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2040
U.S. locations: 27
States / cities: Little Rock, Arkansas • Duarte, California • San Diego, California + 21 more

Conditions: Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blasts Under 25 Percent of Bone Marrow Nucleated Cells, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Burkitt Leukemia, Chronic Monocytic Leukemia, Lymphoblastic Lymphoma, Mast Cell Leukemia, Myeloproliferative Neoplasm
Interventions: Total-Body Irradiation, Thiotepa, Fludarabine, Cyclophosphamide, Busulfan, Allogeneic Bone Marrow Transplantation, Tacrolimus, Methotrexate, Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation, Echocardiography, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy; Radiation · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 6 Months to 26 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Atlanta, Georgia • Iowa City, Iowa + 5 more

Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: fulvestrant, anastrozole; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 856
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 524 more

Conditions: Respiratory Tract Infections
Interventions: Placebo, BEZ235, BEZ235 plus everolimus (RAD001); Other · Drug
Lead sponsor: Restorbio Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 652 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Wichita, Kansas

Conditions: Urinary Tract Infections, Pelvic Organ Prolapse, Urinary Incontinence
Interventions: Nitrofurantoin Prophylaxis/Placebo, Cranberry capsules; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer, Endometrial Cancer, Ovarian Cancer, Corpus Uteri, Endometrium
Interventions: Questionnaire; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 1,315 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma; Renal Cell Carcinoma
Interventions: Blood collection for laboratory studies, Data collection from medical record; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Autism Spectrum Disorder, Autism, Asperger's Syndrome, Pervasive Developmental Disorder
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Months and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Interventions: Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax, Lenalidomide, Pirtobrutinib; Biological · Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • California City, California • Duarte, California + 18 more

Conditions: Femoral Artery, Cannulation
Interventions: Ultrasound with Sacral lift; Diagnostic Test
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 85 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Erie, Pennsylvania

Conditions: Osteoarthritis, Knee
Interventions: Pentosan Polysulfate Sodium twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Pentosan Polysulfate Sodium Fixed Dose, Pentosan Polysulfate Sodium once weekly; Drug
Lead sponsor: Paradigm Biopharmaceuticals USA (INC); Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 29
States / cities: Tempe, Arizona • Tucson, Arizona • Cerritos, California + 20 more

Conditions: Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Mezigdomide, Positron Emission Tomography; Procedure · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer
Interventions: Ivosidenib, mFOLFIRINOX; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Collecting Bone Graft During Spinal Decompression and Posterolateral Lumbar Fusion to Better Define Bone Making Cells

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

Hearing Healthcare Assessment in Rural Communities

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors

Clinical Investigation of the da Vinci Surgical System

Pyloroplasty Versus No Pyloroplasty in Patients Undergoing Esophagectomy

REsearching Covid-19 Outcomes in Diabetes (RECODE)

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly

Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery

Estrogen, Diet, Genetics and Endometrial Cancer

Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

Genetic Contributions to Autism Spectrum Disorders

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Effect of a Sacral Lift on Femoral Vein Size and Exposure

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma